Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Stony Brook University
mi
from
Stony Brook, NY
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Stony Brook University
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Carolinas Hematology-Oncology
mi
from
Charlotte, NC
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Carolinas Hematology-Oncology
mi
from
Charlotte, NC
Click here to add this to my saved trials
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Mercy Physicians of Oklahoma
mi
from
Oklahoma City, OK
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Mercy Physicians of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Cancer Care Associates
mi
from
Tulsa, OK
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Cancer Care Associates
mi
from
Tulsa, OK
Click here to add this to my saved trials
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Pinnacle Health
mi
from
Harrisburg, PA
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Pinnacle Health
mi
from
Harrisburg, PA
Click here to add this to my saved trials
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
The Jones Clinic, PC
mi
from
Germantown, TN
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Scott and White Healthcare
mi
from
Temple, TX
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Scott and White Healthcare
mi
from
Temple, TX
Click here to add this to my saved trials
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Northwest Medical Specialties
mi
from
Tacoma, WA
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Northwest Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Grand River Regional Cancer Centre
mi
from
Kitchener,
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Grand River Regional Cancer Centre
mi
from
Kitchener,
Click here to add this to my saved trials
Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)
Treatment of Tobacco Dependence in Breast Cancer Patients: A Randomized Trial of Varenicline (Chantix)
Status: Enrolling
Updated:  12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)
Treatment of Tobacco Dependence in Breast Cancer Patients: A Randomized Trial of Varenicline (Chantix)
Status: Enrolling
Updated: 12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Status: Enrolling
Updated:  12/22/2015
University of Michigan
mi
from
Ann Arbor, MI
Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Status: Enrolling
Updated: 12/22/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy
Status: Enrolling
Updated:  12/22/2015
St. Mary's Duluth Clinic Health System
mi
from
Duluth, MN
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy
Status: Enrolling
Updated: 12/22/2015
St. Mary's Duluth Clinic Health System
mi
from
Duluth, MN
Click here to add this to my saved trials
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy
Status: Enrolling
Updated:  12/22/2015
Tom Baker Cancer Center - Calgary
mi
from
Calgary,
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy
Status: Enrolling
Updated: 12/22/2015
Tom Baker Cancer Center - Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
John P. Thropay, MD
mi
from
Montebello, CA
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
John P. Thropay, MD
mi
from
Montebello, CA
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Mile High Oncology
mi
from
Denver, CO
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Mile High Oncology
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
LSU Health Sciences Center
mi
from
Shreveport, LA
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
LSU Health Sciences Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Portland VA Medical Center
mi
from
Portland, OR
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Portland VA Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Medical University of South Carolina
mi
from
Charleston, SC
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated:  12/22/2015
Princess Margaret Hospital
mi
from
Toronto,
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease
Status: Enrolling
Updated: 12/22/2015
Princess Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies
Status: Enrolling
Updated:  12/22/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies
Status: Enrolling
Updated: 12/22/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies
Status: Enrolling
Updated:  12/22/2015
Wayne State University, Karmanos Cancer Center
mi
from
Detroit, MI
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies
Status: Enrolling
Updated: 12/22/2015
Wayne State University, Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Urology Database to Evaluate Clinical Information and Improve Patient Care.
Urology Database for Outcomes Research
Status: Enrolling
Updated:  12/22/2015
William Beaumont Hospital
mi
from
Royal Oak, MI
Urology Database to Evaluate Clinical Information and Improve Patient Care.
Urology Database for Outcomes Research
Status: Enrolling
Updated: 12/22/2015
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/22/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/22/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/22/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/22/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/22/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/22/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/22/2015
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/22/2015
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor For the Treatment of Lymphohematopoietic Disorders
Status: Enrolling
Updated:  12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor For the Treatment of Lymphohematopoietic Disorders
Status: Enrolling
Updated: 12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Status: Enrolling
Updated:  12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Status: Enrolling
Updated: 12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/22/2015
Florida Cancer Specialists
mi
from
Fort Myers, FL
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/22/2015
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/22/2015
Suburban Hem Onc
mi
from
Lawrenceville, GA
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/22/2015
Suburban Hem Onc
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/22/2015
Oncology Hematology Care
mi
from
Cincinnati, OH
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/22/2015
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/22/2015
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/22/2015
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/22/2015
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/22/2015
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/22/2015
Family Cancer Center
mi
from
Collerville, TN
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/22/2015
Family Cancer Center
mi
from
Collerville, TN
Click here to add this to my saved trials
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/22/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/22/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/22/2015
Virginia Cancer Institute
mi
from
Richmond, VA
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/22/2015
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin and 5-fluorouracil (5-FU) Followed by Hepatic Arterial Infusion of FUDR for Patients With Unresectable Colorectal Liver Metastases
Status: Enrolling
Updated:  12/23/2015
UPMC Cancer Centers Network
mi
from
Pittsburgh, PA
Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin and 5-fluorouracil (5-FU) Followed by Hepatic Arterial Infusion of FUDR for Patients With Unresectable Colorectal Liver Metastases
Status: Enrolling
Updated: 12/23/2015
UPMC Cancer Centers Network
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials